Anti-infective prophylaxis in pediatric patients with acute myeloid leukemia

Expert Review of Hematology

Volumn 7, Issue 6, 2014, Pages 819-830

  Lehrnbecher, Thomas ^a   Sung, Lillian ^b  

^a GOETHE UNIVERSITY   (Germany)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Acute myeloid leukemia; Bacteria; Child; Fungus; Granulocyte transfusion; Hematopoietic growth factor; Infection

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; ANTIINFECTIVE AGENT; INTERLEUKIN 3;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; CANCER CHEMOTHERAPY; CANCER PATIENT; CHILD; CHILDHOOD CANCER; DRUG EFFICACY; GRAFT RECIPIENT; GRAM NEGATIVE BACTERIUM; GRANULOCYTE TRANSFUSION; HIGH RISK PATIENT; HUMAN; INFECTION PREVENTION; INFECTION RISK; INFECTIOUS COMPLICATION; INTESTINE FLORA; MICROBIAL DIVERSITY; MYCOSIS; NONHUMAN; PALLIATIVE THERAPY; REVIEW; BACTERIAL INFECTIONS; COMPLICATION; LEUKEMIA, MYELOID, ACUTE; LEUKOCYTE TRANSFUSION; MYCOSES;

ANTI-INFECTIVE AGENTS; BACTERIAL INFECTIONS; CHILD; HEMATOPOIETIC CELL GROWTH FACTORS; HUMANS; LEUKEMIA, MYELOID, ACUTE; LEUKOCYTE TRANSFUSION; MYCOSES;

EID: 84911363874     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/17474086.2014.965140     Document Type: Review

References (101)

1. Lehrnbecher T, Varwig D, Kaiser J, et al. Infectious complications in pediatric acute myeloid leukemia: analysis of the prospective multi-institutional clinical trial AML-BFM 93. Leukemia 2004;18:72-7
2. Chamilos G, Luna M, Lewis RE, et al. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). Haematologica 2006;91:986-9
3. Sung L, Lange BJ, Gerbing RB, et al. Microbiologically documented infections and infection-related mortality in children with acute myeloid leukemia. Blood 2007;110:3532-9
4. Gassas A, Grant R, Richardson S, et al. Predictors of viridans streptococcal shock syndrome in bacteremic children with cancer and stem-cell transplant recipients. J Clin Oncol 2004;22:1222-7
5. Lewis V, Yanofsky R, Mitchell D, et al. Predictors and outcomes of viridans group streptococcal infections in pediatric acute myeloid leukemia: from the Canadian infections in AML research group. Pediatr Infect Dis J 2014;33:126-9
6. Johnston DL, Lewis V, Yanofsky R, et al. Invasive fungal infections in paediatric acute myeloid leukaemia. Mycoses 2013;56:482-7
7. Sung L. Invasive fungal infections in children with cancer. J Pediatr 2010; 156(Suppl 2):S68-73
8. Molgaard-Hansen L, Mottonen M, Glosli H, et al. Early and treatment-related deaths in childhood acute myeloid leukaemia in the Nordic countries: 1984-2003. Br J Haematol 2010;151: 447-59
9. Creutzig U, Zimmermann M, Reinhardt D, et al. Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98. J Clin Oncol 2004;22: 4384-93
10. Dix D, Cellot S, Price V, et al. Association between corticosteroids and infection, sepsis, and infectious death in pediatric acute myeloid leukemia (AML): results from the Canadian infections in AML research group. Clin Infect Dis 2012;55:1608-14
11. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011;52:427-31
12. Oren I, Haddad N, Finkelstein R, Rowe JM. Invasive pulmonary aspergillosis in neutropenic patients during hospital construction: before and after chemoprophylaxis and institution of HEPA filters. Am J Hematol 2001;66: 257-62
13. Fennell JP, O'Donohoe M, Cormican M, Lynch M. Linezolid lock prophylaxis of central venous catheter infection. J Med Microbiol 2008;57:534-5
14. Fernandez-Gallego J, Alonso A, Sujan S, Gutierrez E. [Prophylaxis with gentamycin reduces bacterial infection morbidity and mortality caused by permanent tunneled central venous catheter]. Nefrologia 2007;27:228-9
15. Moody K, Charlson ME, Finlay J. The neutropenic diet: whats the evidence? J Pediatr Hematol Oncol 2002;24:717-21
16. van Dalen EC, Mank A, Leclercq E, et al. Low bacterial diet versus control diet to prevent infection in cancer patients treated with chemotherapy causing episodes of neutropenia. Cochrane Database Syst Rev 2012;9:CD006247
17. Zitella LJ, Friese CR, Hauser J, et al. Putting evidence into practice: prevention of infection. Clin J Oncol Nurs 2006;10: 739-50
18. Robert-Koch Institut (RKI) KfKuIbRK-I. Anforderungen an die Hygiene bei der medizinischen Versorgung von immunsupprimierten Patienten. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2010;53:357-88
19. US Department of Agriculture. Food safety of people with cancer. Available from: www.fsis.usda.gov/PDF/Food-Safety-for-People-with-Cancer.pdf [Last accessed 6 June 2014]
20. Lehrnbecher T, Aplenc R, Rivas Pereira F, et al. Variations in non-pharmacological anti-infective measures in childhood leukemia-results of an international survey. Haematologica 2012;97:1548-52
21. Sung L, Aplenc R, Alonzo TA, et al. Effectiveness of supportive care measures to reduce infections in pediatric AML: a report from the Children's Oncology Group. Blood 2013;121:3573-7
22. Lehrnbecher T, Ethier MC, Zaoutis T, et al. International variations in infection supportive care practices for paediatric patients with acute myeloid leukaemia. Br J Haematol 2009;147:125-8
23. Taur Y, Xavier JB, Lipuma L, et al. Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Infect Dis 2012;55:905-14
24. Buzyn A, Tancrede C, Nitenberg G, Cordonnier C. The Cg. Reflections on gut decontamination in hematology. Clin Microbiol Infect 1999;5:449-56
25. Bow EJ. Management of the febrile neutropenic cancer patient: lessons from 40 years of study. Clin Microbiol Infect 2005;11(Suppl 5):24-9
26. van de Wetering MD, de Witte MA, Kremer LC, et al. Efficacy of oral prophylactic antibiotics in neutropenic afebrile oncology patients: a systematic review of randomised controlled trials. Eur J Cancer 2005;41:1372-82
27. Bucaneve G, Micozzi A, Menichetti F, et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 2005;353:977-87
28. Gafter-Gvili A, Fraser A, Paul M, Leibovici L. Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 2005;142:979-95
29. Lingaratnam S, Thursky KA, Slavin MA. Fluoroquinolone prophylaxis: a word of caution. Leuk Lymphoma 2011;52:5-6
30. Cruciani M, Malena M, Bosco O, et al. Reappraisal with meta-analysis of the addition of Gram-positive prophylaxis to fluoroquinolone in neutropenic patients. J Clin Oncol 2003;21:4127-37
31. Kurt B, Flynn P, Shenep JL, et al. Prophylactic antibiotics reduce morbidity due to septicemia during intensive treatment for pediatric acute myeloid leukemia. Cancer 2008;113:376-82
32. Inaba H, Gaur AH, Cao X, et al. Feasibility, efficacy, and adverse effects of outpatient antibacterial prophylaxis in children with acute myeloid leukemia. Cancer 2014;120(13):1985-92
33. Santolaya ME, Rabagliati R, Bidart T, et al. [Consensus: Rational approach towards the patient with cancer, fever and neutropenia]. Rev Chilena Infectol 2005;22(Suppl 2): S79-113
34. Link H, Bohme A, Cornely OA, et al. Antimicrobial therapy of unexplained fever in neutropenic patients-guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG-German Cancer Society). Ann Hematol 2003;82(Suppl 2):S105-17
35. Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009;15:1143-238
36. National Comprehensive Cancer Network (NCCN). Prevention and Treatment of Cancer-Related Infections v.2. 2009; Available from: www.nccn.org/professionals/physician-gls/f-guidelines.asp#supportive [[Last accessed 6 June 2014]
37. Diorio C, Tomlinson D, Boydell KM, et al. Attitudes toward infection prophylaxis in pediatric oncology: a qualitative approach. PLoS One 2012;7:e47815
38. Regier DA, Diorio C, Ethier MC, et al. Discrete choice experiment to evaluate factors that influence preferences for antibiotic prophylaxis in pediatric oncology. PLoS One 2012;7:e47470
39. Kern WV, Klose K, Jellen-Ritter AS, et al. Fluoroquinolone resistance of Escherichia coli at a cancer center: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia. Eur J Clin Microbiol Infect Dis 2005;24:111-18
40. Saini L, Rostein C, Atenafu EG, Brandwein JM. Ambulatory consolidation chemotherapy for acute myeloid leukemia with antibacterial prophylaxis is associated with frequent bacteremia and the emergence of fluoroquinolone resistant E. Coli. BMC Infect Dis 2013;13:284
41. Persson L, Vikerfors T, Sjoberg L, et al. Increased incidence of bacteraemia due to viridans streptococci in an unselected population of patients with acute myeloid leukaemia. Scand J Infect Dis 2000;32: 615-21
42. Kotilainen P, Nikoskelainen J, Huovinen P. Emergence of ciprofloxacin-resistant coagulase-negative staphylococcal skin flora in immunocompromised patients receiving ciprofloxacin. J Infect Dis 1990;161:41-4
43. Pepin J, Saheb N, Coulombe MA, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005;41:1254-60
44. Muto CA, Pokrywka M, Shutt K, et al. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 2005;26:273-80
45. Gamis AS, Howells WB, DeSwarte-Wallace J, et al. Alpha hemolytic streptococcal infection during intensive treatment for acute myeloid leukemia: a report from the Children's cancer group study CCG-2891. J Clin Oncol 2000;18: 1845-55
46. Tunkel AR, Sepkowitz KA. Infections caused by viridans streptococci in patients with neutropenia. Clin Infect Dis 2002;34: 1524-9
47. Spanik S, Trupl J, Kunova A, et al. Viridans streptococcal bacteraemia due to penicillin-resistant and penicillin-sensitive streptococci: analysis of risk factors and outcome in 60 patients from a single cancer centre before and after penicillin is used for prophylaxis. Scand J Infect Dis 1997;29: 245-9
48. Worth LJ, Thursky KA, Seymour JF, Slavin MA. Vancomycin-resistant Enterococcus faecium infection in patients with hematologic malignancy: patients with acute myeloid leukemia are at high-risk. Eur J Haematol 2007;79:226-33
49. Barker GJ, Call SK, Gamis AS. Oral care with vancomycin paste for reduction in incidence of alpha-hemolytic streptococcal sepsis. J Pediatr Hematol Oncol 1995;17: 151-5
50. Hampel B, Hullmann R, Schmidt H. Ciprofloxacin in pediatrics: worldwide clinical experience based on compassionate use-safety report. Pediatr Infect Dis J 1997;16:127-9; discussion 160-122
51. Noel GJ, Bradley JS, Kauffman RE, et al. Comparative safety profile of levofloxacin in 2523 children with a focus on four specific musculoskeletal disorders. Pediatr Infect Dis J 2007;26:879-91
52. Richard DA, Nousia-Arvanitakis S, Sollich V, et al. Oral ciprofloxacin vs. intravenous ceftazidime plus tobramycin in pediatric cystic fibrosis patients: comparison of antipseudomonas efficacy and assessment of safety with ultrasonography and magnetic resonance imaging. Cystic Fibrosis Study Group. Pediatr Infect Dis J 1997;16:572-8
53. Pizzo P, Robichaud K, Edwards B, et al. Oral antibiotic prophylaxis in patients with cancer: A double blind randomized placebo controlled trial. J Pediatr 1983;102:125
54. Lehrnbecher T, Laws HJ, Boehm A, et al. Compliance with anti-infective preventive measures: a multicentre survey among paediatric oncology patients. Eur J Cancer 2008;44:1861-5
55. Creutzig U, van den Heuvel-Eibrink MM, Gibson B, et al. Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Blood 2012;120: 3187-205
56. Sung L, Zaoutis T, Ullrich NJ, et al. Children's Oncology Groups 2013 blueprint for research: cancer control and supportive care. Pediatr Blood Cancer 2013;60:1027-30
57. Alexander S, Nieder M, Zerr DM, et al. Prevention of bacterial infection in pediatric oncology: what do we know, what can we learn? Pediatr Blood Cancer 2012;59:16-20
58. Groll AH, Castagnola E, Cesaro S, et al. Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation. Lancet Oncol 2014;15:e327-40
59. Nucci M, Anaissie E. Revisiting the source of candidemia: skin or gut? Clin Infect Dis 2001;33:1959-67
60. Segal BH. Aspergillosis. N Engl J Med 2009;360:1870-84
61. Science M, Robinson PD, MacDonald T, et al. Guideline for primary antifungal prophylaxis for pediatric patients with cancer or hematopoietic stem cell transplant recipients. Pediatr Blood Cancer 2014;61: 393-400
62. Groll AH, Tragiannidis A. Recent advances in antifungal prevention and treatment. Semin Hematol 2009;46:212-29
63. Penack O, Schwartz S, Martus P, et al. Low-dose liposomal amphotericin B in the prevention of invasive fungal infections in patients with prolonged neutropenia: results from a randomized, single-center trial. Ann Oncol 2006;18:1306-12
64. Bochennek K, Tramsen L, Schedler N, et al. Liposomal amphotericin B twice weekly as antifungal prophylaxis in pediatric high risk patients. Clin Microbiol Infect 2011;17:1868-74
65. Rijnders BJ, Cornelissen JJ, Slobbe L, et al. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial. Clin Infect Dis 2008;46:1401-8
66. Hullard-Pulstinger A, Holler E, Hahn J, et al. Prophylactic application of nebulized liposomal amphotericin B in hematologic patients with neutropenia. Onkologie 2011;34:254-8
67. Menichetti F, Del Favero A, Martino P, et al. The GIMEMA Infection Program. Preventing fungal infection in neutropenic patients with acute leukemia: fluconazole compared with oral amphotericin B. Ann Intern Med 1994;120:913-18
68. Ashbee HR, Barnes RA, Johnson EM, et al. Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. J Antimicrob Chemother 2014;69:1162-76
69. Marr KA, Crippa F, Leisenring W, et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 2004;103:1527-33
70. Glasmacher A, Prentice A, Gorschluter M, et al. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3, 597 patients. J Clin Oncol 2003;21:4615-26
71. Vardakas KZ, Michalopoulos A, Falagas ME. Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: a meta-analysis of randomised-controlled trials. Br J Haematol 2005;131:22-8
72. Foot AB, Veys PA, Gibson BE. Itraconazole oral solution as antifungal prophylaxis in children undergoing stem cell transplantation or intensive chemotherapy for haematological disorders. Bone Marrow Transplant 1999;24:1089-93
73. Grigull L, Kuehlke O, Beilken A, et al. Intravenous and oral sequential itraconazole antifungal prophylaxis in paediatric stem cell transplantation recipients: a pilot study for evaluation of safety and efficacy. Pediatr Transplant 2007;11:261-6
74. Tragiannidis A, Dokos C, Lehrnbecher T, Groll AH. Antifungal chemoprophylaxis in children and adolescents with haematological malignancies and following allogeneic haematopoietic stem cell transplantation: review of the literature and options for clinical practice. Drugs 2012;72: 685-704
75. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007;356:348-59
76. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007;356:335-47
77. Wingard JR, Carter SL, Walsh TJ, et al. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood 2010;116:5111-18
78. Marks DI, Pagliuca A, Kibbler CC, et al. Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation. Br J Haematol 2011;155:318-27
79. Vehreschild JJ, Bohme A, Buchheidt D, et al. A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML). J Infect 2007;55:445-9
80. Molina JR, Serrano J, Sanchez-Garcia J, et al. Voriconazole as primary antifungal prophylaxis in children undergoing allo-SCT. Bone Marrow Transplant 2012;47:562-7
81. Mandhaniya S, Swaroop C, Thulkar S, et al. Oral voriconazole versus intravenous low dose amphotericin B for primary antifungal prophylaxis in pediatric acute leukemia induction: a prospective, randomized, clinical study. J Pediatr Hematol Oncol 2011;33:e333-41
82. van Burik JA, Ratanatharathorn V, Stepan DE, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004;39: 1407-16
83. Mattiuzzi GN, Alvarado G, Giles FJ, et al. Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies. Antimicrob Agents Chemother 2006;50:143-7
84. Doring M, Hartmann U, Erbacher A, et al. Caspofungin as antifungal prophylaxis in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation: a retrospective analysis. BMC Infect Dis 2012;12:151
85. Hughes W, Feldman S, Aur R, et al. Intensity of immunosuppressive therapy and incidence of Pneumocystis carinii pneumonia. Cancer 1975;36:2004-9
86. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infections in patients with acute leukemia. Ann Intern Med 1966;64:328-40
87. Schimpff S, Satterlee W, Young V, Serpick A. Empiric therapy with carbenicillin and gentamicin for febrile, patients with cancer and granulocytopenia. N Engl J Med 1971;284:1061-5
88. Schimpff SC, Young VM, Greene WH, et al. Origin of infection in acute nonlymphocytic leukemia: significance of hospital acquisition of potential pathogens. Ann Intern Med 1972;77:707-14
89. Pizzo PA, Robichaud KJ, Wesley R, Commers JR. Fever in the pediatric and young adult patient with cancer. A prospective study of 1001 episodes. Medicine (Baltimore) 1982;61:153-65
90. Lehrnbecher T, Welte K. Haematopoietic growth factors in children with neutropenia. Br J Haematol 2002;116:28-56
91. Sung L, Nathan PC, Alibhai SM, et al. Meta-analysis: effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection. Ann Intern Med 2007;147:400-11
92. Heuser M, Zapf A, Morgan M, et al. Myeloid growth factors in acute myeloid leukemia: systematic review of randomized controlled trials. Ann Hematol 2011;90: 273-81
93. Lowenberg B, Touw IP. Hematopoietic growth factors and their receptors in acute leukemia. Blood 1993;81:281-92
94. Souza LM, Boone TC, Lai PH, et al. Recombinant human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cells. Science 1986;232:61-5
95. Ehlers S, Herbst C, Zimmermann M, et al. Granulocyte colony-stimulating factor (G-CSF) treatment of childhood acute myeloid leukemias that overexpress the differentiation-defective G-CSF receptor isoform IV is associated with a higher incidence of relapse. J Clin Oncol 2010;28: 2591-7
96. Grigull L, Pulver N, Goudeva L, et al. G-CSF mobilised granulocyte transfusions in 32 paediatric patients with neutropenic sepsis. Support Care Cancer 2006;14: 910-16
97. Seidel MG, Minkov M, Witt V, et al. Granulocyte transfusions in children and young adults: does the dose matter? J Pediatr Hematol Oncol 2009;31:166-72
98. Mousset S, Hermann S, Klein SA, et al. Prophylactic and interventional granulocyte transfusions in patients with haematological malignancies and life-threatening infections during neutropenia. Ann Hematol 2005;84: 734-41
99. Massey E, Paulus U, Doree C, Stanworth S. Granulocyte transfusions for preventing infections in patients with neutropenia or neutrophil dysfunction. Cochrane Database Syst Rev 2009(1):CD005341
100. Lehrnbecher T, Koehl U, Wittekindt B, et al. Changes in host defence induced by malignancies and antineoplastic treatment: implication for immunotherapeutic strategies. Lancet Oncol 2008;9:269-78
101. Lehrnbecher T, Bernig T, Hanisch M, et al. Common genetic variants in the interleukin-6 and chitotriosidase genes are associated with the risk for serious infection in children undergoing therapy for acute myeloid leukemia. Leukemia 2005;19: 1745-50